BiotechTube
Protein Fluidics

Protein Fluidics

Cambridge, United States· Est.
proteinfluidics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Founded in 2016, Protein Fluidics is a private, venture-backed company commercializing the Pu·MA System, an integrated instrument and consumable platform for automating assays on 3D cell models. The technology addresses critical bottlenecks in organoid and spheroid research by dramatically reducing hands-on time and improving assay reproducibility and sensitivity. Targeting the research tools market within proteomics and diagnostics, the company is in the early revenue stage, leveraging a platform business model to enable data-driven decisions in drug discovery and translational research.

OncologyNeuroscience

Technology Platform

Pu·MA System: A bench-top microfluidic automation platform using disposable flowchips for precise, hands-off assay processing of 3D cell models (organoids, spheroids). Enables automated immunofluorescence staining, co-cultures, sequential drug additions, and supernatant sampling with minimal perturbation.

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The rapid adoption of 3D cell models in drug discovery and personalized medicine creates a large, growing market for specialized automation.
The company's open-platform strategy positions it to become a standard workflow tool, driving recurring consumable revenue.
Strategic investor backing provides potential for commercial partnerships and non-dilutive growth channels.

Risk Factors

Competition from larger, established life science tool companies with greater resources and sales reach poses a significant threat.
Market adoption may be slow as researchers are often hesitant to change core manual protocols.
As a small private company, it remains dependent on investor funding to achieve scale and sustainable cash flow.

Competitive Landscape

Protein Fluidics competes in the niche of 3D cell model automation. Direct competitors may include other startups developing microfluidic organoid platforms (e.g., AIM Biotech, Emulate). Indirect competition comes from manual protocols, generic liquid handlers requiring extensive customization, and high-content screening systems from large players like Revvity, Molecular Devices, and Agilent, which may add 3D-specific capabilities.

More companies in Diagnostics & Precision Medicine →More companies in United States →